Non-small cell lung carcinoma

This Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…

This early-phase trial is testing whether combining two drugs—vismodegib and atezolizumab—is safe and tolerable for people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer cells grow, while atezolizumab helps…

This trial tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) that is PD-L1 negative. The goal is to see if the vaccine can train the immune system to destroy any remain…

This study tests whether adding local treatments like surgery or radiation to a combination of two immunotherapy drugs (nivolumab and ipilimumab) helps people with stage IV non-small cell lung cancer live longer compared to immunotherapy alone. About 339 participants who have not…

This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage I…

This study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 173 participants will receive either osimertinib alone or osimertinib plus lo…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This early-stage trial tests whether combining two drugs, ceritinib and nivolumab, is safe and effective for people with a specific genetic subtype of advanced lung cancer called ALK-positive NSCLC. About 57 adults with stage IIIB or IV disease will receive the combination. The m…

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This phase 3 trial compares a new drug, divarasib, to two existing targeted therapies (sotorasib and adagrasib) in 338 people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has progressed after prior treatment. Participants take …

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This study tests whether giving a higher radiation dose directly to the tumor, while keeping the standard dose to surrounding healthy tissue, can improve outcomes for people with stage II to IIIB non-small cell lung cancer. About 146 participants will receive either photon (IMRT)…

This study tests the safety and best dose of adding telaglenastat to the standard drug osimertinib for people with stage IV non-small cell lung cancer that has a specific EGFR mutation. The two drugs work together to block enzymes that cancer cells need to grow. The trial involve…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This phase 2 trial tests a new drug called THIO, which targets telomeres in cancer cells, followed by the immunotherapy cemiplimab (LIBTAYO) in people with advanced non-small cell lung cancer. The study includes about 227 participants whose cancer has progressed after initial tre…

This study tests an experimental drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 participants will take part.

This phase II trial tests a new approach for advanced non-small cell lung cancer that hasn't responded to standard treatments. It combines photoimmunotherapy (ASP-1929), a light-activated drug that targets cancer cells, with cemiplimab, an immunotherapy that boosts the immune sys…

This phase 3 trial tests whether adding savolitinib to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR-mutant, MET-positive non-small cell lung cancer). About 412 participants will receive either the combination or a placebo plus osim…

This early-stage trial is testing whether combining valemetostat tosylate with two different antibody-drug conjugates (T-DXd or Dato-DXd) is safe and effective for people with advanced solid tumors. About 210 adults with at least one measurable tumor will receive the drugs orally…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This program provides early access to divarasib, an experimental oral drug designed to target the KRAS G12C mutation found in some non-small cell lung cancers. It is open to adults with advanced or metastatic disease that has progressed after at least one prior standard treatment…

This early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for patients with stage II or III non-small cell lung cancer that cannot be surgically removed. The study enrolls 21 participants who hav…

This study tests a drug called sacituzumab govitecan combined with pembrolizumab (and sometimes chemotherapy) as a first treatment for people with advanced or metastatic non-small-cell lung cancer that lacks specific genetic changes. About 193 participants will receive these comb…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This early-phase trial is testing whether combining two drugs, amivantamab and tepotinib, can help control non-small cell lung cancer with MET alterations. Only 3 adults with advanced disease that cannot be surgically removed are enrolled. The main goal is to check safety and see…

This Phase II trial tests whether adding olaparib to durvalumab helps keep stage IV non-small cell lung cancer from growing after initial chemotherapy. About 400 patients whose cancer did not worsen on standard chemo plus durvalumab will receive either the combination or durvalum…

This study tests whether adding the immunotherapy drug nivolumab after surgery and chemotherapy helps prevent non-small cell lung cancer from coming back. About 900 adults with stage IB to IIIA lung cancer who had their tumor completely removed are participating. The goal is to s…

This phase 3 trial tests a daily pill called osimertinib (AZD9291) against a placebo in 682 people with a specific type of lung cancer (EGFR-mutated, stages IB to IIIA) who have had surgery to remove their tumor. The goal is to see if the drug can delay or prevent the cancer from…

This Phase 3 trial is testing a new drug called sacituzumab tirumotecan (MK-2870) against standard platinum-based chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened despite prior targeted t…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This study tests two new treatments—cabozantinib alone or with nivolumab—against standard chemotherapy for people with advanced non-squamous lung cancer that has returned. The goal is to see if these combinations can slow cancer growth better than current options. About 117 adult…

This early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…

This study compares a new, potentially more affordable drug called MB12 (a biosimilar to Keytruda) to the original Keytruda, both given with chemotherapy, as a first treatment for people with advanced stage IV non-squamous non-small cell lung cancer. About 726 adults who have not…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study tested giving the immunotherapy drugs nivolumab (with or without ipilimumab) before surgery to people with a type of lung cancer called non-small-cell lung cancer. The goal was to see if this approach is safe and helps shrink tumors before removal. 39 participants were…

This phase 2 trial tests a combination of three drugs—tiragolumab, atezolizumab, and bevacizumab—in people with advanced non-squamous non-small cell lung cancer that has already been treated. The goal is to see if the combination can shrink tumors or slow disease progression. Abo…

This phase II trial tests whether adding two types of precisely targeted radiation (BgRT and SBRT) to the standard drug osimertinib can better control advanced EGFR-positive lung cancer that has started to grow in a few new spots. About 32 adults with this specific type of lung c…

This early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.

This study tests a new drug called JDQ443 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation) and does not respond well to standard treatments. The drug is taken as a pill and aims to shrink or control the cancer. About 95 participants will…

This Phase 3 trial tests whether a combination of two immunotherapy drugs (acasunlimab and pembrolizumab) works better than the standard chemotherapy docetaxel for people with a specific type of advanced lung cancer (PD-L1 positive NSCLC) that has worsened after prior treatment. …

This phase 2 trial is testing whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or radiation can help people with stage IIB-IIIB non-small cell lung cancer. The study includes 142 participants whose tumors are considered removable or…

This study offers continued treatment with capmatinib for people with advanced solid tumors that depend on a protein called cMET. It includes 29 participants who were already benefiting from capmatinib in a previous Novartis trial. The main goal is to monitor long-term safety and…

This phase 2 trial tests two drugs, erlotinib and cabozantinib, given alone or together in 125 patients with advanced non-small cell lung cancer that does not have a common EGFR mutation. The goal is to see if the combination works better than either drug alone to slow cancer gro…

This phase 3 trial tests whether giving the targeted drug osimertinib (Tagrisso) before surgery, alone or with chemotherapy, works better than standard chemotherapy alone for people with a specific type of lung cancer (EGFR-mutant, non-small cell). About 358 patients with stage I…

This phase 2 trial tests a combination of two drugs—ceralasertib (a pill) and durvalumab (an infusion)—in 39 adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The main goal is to see if t…

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced lung cancer that has a specific EGFR gene mutation. About 60 adults with newly diagnosed or recurrent non-small cell lung cancer that cannot be surgically removed will …

This phase III trial studies whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage 3 non-small cell lung cancer that cannot be surgically removed. About 660 participants will receive either chemoradiation plus durvaluma…

This phase II trial is testing whether combining the targeted drug trametinib with the chemotherapy docetaxel can shrink tumors in people with advanced KRAS-mutant non-small cell lung cancer. The study enrolls 60 patients whose cancer has worsened after one or two prior treatment…

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This large study is testing several targeted therapies and immunotherapies for people with advanced non-small cell lung cancer. Instead of a tissue biopsy, a simple blood test is used to find specific genetic changes in the cancer. The goal is to see if matching the right drug to…

This study tests a daily pill called adagrasib in 68 patients with a specific type of advanced lung cancer (KRAS G12C mutation) who are either 70 or older or have poor physical health. The goal is to see if the drug can shrink tumors or stop them from growing. Patients take the m…

This study tests whether combining two drugs, savolitinib and durvalumab, can help control advanced lung cancer in people whose tumors have a specific genetic change called MET alteration. About 47 adults in China with non-small cell lung cancer that has spread will receive the c…

This study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) helps people with advanced EGFR-mutated non-small cell lung cancer live longer without their cancer worsening. About 587 adults with newly diagnosed or recurrent advanced lung cancer will be …

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This phase III trial is testing whether giving chemotherapy and immunotherapy both before and after surgery (perioperative) is better than giving it only after surgery (adjuvant) for people with stage II-IIIB non-small cell lung cancer that can be removed. About 1,100 participant…

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This early-phase trial tests a new drug called KQB198 in adults with advanced solid tumors that have not responded to other treatments. The study aims to find a safe dose and see if KQB198 can shrink tumors when used alone or with other cancer drugs. About 100 participants will t…

This study compares a new drug, BAT3306, to the approved drug Keytruda in people with stage IB-IIIA non-small cell lung cancer whose tumors have been completely removed by surgery. The goal is to see if BAT3306 works similarly as an additional treatment to help keep the cancer fr…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …

This study tests whether combining two drugs, atezolizumab and cobimetinib, can help people with advanced non-small cell lung cancer whose tumors stopped responding to standard immunotherapy. About 51 adults with metastatic or recurrent lung cancer will receive the combination. T…

This study tests an experimental drug called patritumab deruxtecan in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to other treatments. About 277 participants will receive the drug to see if it shrinks tumors. The go…

This study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…

This phase 3 study compares the experimental drug poziotinib to the standard chemotherapy docetaxel in 268 people with advanced non-small cell lung cancer that has a specific HER2 mutation. Participants must have already tried at least one prior treatment. The main goal is to see…

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, with or without chemotherapy, in 301 people with stage IV non-small cell lung cancer. The goal is to see if these drugs help patients live longer by helping their immune system fight the cancer. Participants m…

This phase 3 study tests whether adding the targeted drug amivantamab to standard chemotherapy helps people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). About 308 participants will receive either the combination or chemotherapy a…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells by attaching to them and blocking growth. About 11…

This phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The study includes 169 participants and aims to see if t…

This early-phase trial is testing whether adding two drugs, dupilumab and anakinra, to standard immunotherapy can help people with advanced non-small cell lung cancer whose cancer has stopped responding to treatment. About 33 participants will receive the combination to see if it…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This study tests a new drug called volrustomig combined with other cancer treatments for people with advanced non-small cell lung cancer. The main goals are to check safety and see if tumors shrink. About 180 adults will take part in this early-stage trial.

This study tests a new form of the drug amivantamab that can be given as a shot under the skin, combined with the pill lazertinib, for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after prior treatments. The goal …

This early-stage trial tests an experimental drug called DM001 in people with advanced solid tumors, including breast cancer, non-small cell lung cancer, and other solid cancers that have progressed on standard treatment. The main goals are to find a safe dose, identify side effe…

This phase 2 trial tests a combination of two drugs, olomorasib and pembrolizumab, as a first treatment for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and a PD-L1 score between 1% and 49%. The main goal is to see how long patients live without t…

This phase 3 trial compares a combination of two targeted drugs, amivantamab and lazertinib, against the standard drug osimertinib as a first treatment for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). About 1,074 participants will…

This early-stage trial is testing a new drug called JNJ-86974680, alone or with another drug (cetrelimab) and radiation, in people with advanced non-small cell lung cancer. The main goal is to find a safe and tolerable dose. About 126 participants will be enrolled. The study is c…

This early-stage trial tests a new drug called amivantamab in people with advanced non-small cell lung cancer. The drug is a special antibody that targets two proteins on cancer cells. Researchers are checking safety and how well it works, both alone and with other treatments. Ab…

This study looks at whether special skin care can lower the chance of bad skin reactions in people with advanced lung cancer who are taking a combination of two drugs (amivantamab and lazertinib). About 305 participants will be randomly assigned to standard skin care or enhanced …

This study tests a combination of two drugs, amivantamab and capmatinib, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combination shrinks tumors. About 57 participants will be enrolled, and the study is curre…

This study tests whether adding a second immunotherapy drug (domvanalimab) to the standard drug durvalumab can better control stage III lung cancer that hasn't grown after initial chemo-radiation. About 860 adults with a specific type of lung cancer will receive either the combo …

This early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The goal is to check safety and find the right dose, both when used alone and with other cancer drugs. About 498 participants will…

This early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This phase III trial is testing two different treatment sequences for people with advanced non-squamous non-small cell lung cancer. One group starts with the immunotherapy drug pembrolizumab alone, then adds chemotherapy only if the cancer progresses. The other group receives pem…

This study tests two experimental drugs, SI-B001 and SI-B003, given together with or without chemotherapy in 160 people with advanced non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the combination shrinks tumors. Participants must …

This study looks at whether adding a precise, high-dose form of radiation (SBRT) to standard chemotherapy and immunotherapy (nivolumab) before surgery can improve outcomes for people with stage IIA to IIIB non-small cell lung cancer. About 17 participants were randomly assigned t…

This phase 3 trial compares an experimental drug called patritumab deruxtecan with standard platinum-based chemotherapy in people with a specific type of non-small cell lung cancer that has an EGFR mutation and has progressed after EGFR-targeted therapy. The drug is designed to d…

This trial is testing an experimental drug called BL-M07D1 in people with a specific type of advanced non-small cell lung cancer that has a HER2 mutation. The study aims to find the best dose and see how well the drug shrinks tumors, while also checking for side effects. Particip…

This Phase 3 trial compares a new oral drug, JDQ443, to the standard chemotherapy docetaxel in about 95 people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. Participants have already tried platinum-based chemo and an immunotherapy drug. The stud…

This phase 3 trial tests whether adding the immunotherapy drug nivolumab (Opdivo) to standard chemotherapy before and after surgery can help people with early-stage non-small cell lung cancer live longer without their cancer coming back. About 461 participants will receive either…

This study compares a new drug, DS-1062a, to the standard chemotherapy docetaxel in about 600 adults with advanced or metastatic non-small cell lung cancer that has worsened after previous treatment. The goal is to see if DS-1062a can slow cancer growth or extend survival better …

This phase 3 trial tests whether adding the targeted drug zipalertinib to standard chemotherapy can delay or prevent lung cancer from returning in people with early-stage non-small cell lung cancer (stages IB to IIIA) who have uncommon EGFR mutations. After complete tumor removal…

This phase 3 trial compares a new subcutaneous (under-the-skin) injection of the immunotherapy drug pembrolizumab, combined with chemotherapy, against the standard intravenous (IV) infusion for people with metastatic non-small cell lung cancer who have not had prior treatment. Th…

This study tests whether a subcutaneous (under-the-skin) injection of pembrolizumab works as well as the standard IV infusion for people with metastatic non-small cell lung cancer. About 39 Japanese adults will receive either the shot or the IV, both combined with chemotherapy. T…

This study offers continued access to the drug lorlatinib for people with a specific type of lung cancer (ALK-positive or ROS1-positive non-small cell lung cancer) who are already benefiting from it in earlier Pfizer studies. The main goal is to track long-term safety and side ef…

This phase 2 pilot trial tested adding the drug bevacizumab to standard chemotherapy and radiation for patients with stage III non-small cell lung cancer that cannot be removed by surgery. The study enrolled 29 newly diagnosed patients to see if the combination is safe and helps …

This early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims t…

This early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This phase 2 trial tests whether adding the cholesterol-lowering drug alirocumab to standard chemotherapy and immunotherapy (cemiplimab) before surgery helps eliminate more cancer in people with stage 1B-3A non-small cell lung cancer. About 126 participants will be randomly assig…

This phase II trial tests a shorter, higher-dose radiation therapy followed by the immunotherapy drug atezolizumab in 47 patients with stage II or III non-small cell lung cancer who have borderline health. The goal is to see if this approach is safe and effective for people who c…

This study tests whether adding a third drug to standard immunotherapy (cemiplimab) plus chemotherapy works better for people with early-stage non-small cell lung cancer who can have surgery. About 120 adults will receive treatment before and after their operation. The main goal …

This phase 2 trial is investigating whether an experimental drug called NC318, given alone or combined with the immunotherapy pembrolizumab, can shrink tumors in people with advanced non-small cell lung cancer. The study includes patients whose cancer has progressed despite prior…

This phase 3 trial tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) whose cancer has stopped responding to the drug osimertinib. Abo…

This study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…

This study provides expanded access to sotorasib, an oral drug designed to target a specific genetic mutation (KRAS G12C) found in some non-small cell lung cancers. It is for adults with advanced or metastatic disease who have already tried standard treatments, including chemothe…

This study tests whether giving the targeted drug osimertinib before and after standard chemoradiation helps control stage III lung cancer that cannot be removed by surgery. About 76 adults with a specific EGFR gene mutation will receive the drug as induction therapy, then contin…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This phase 3 trial tests whether adding the drug Dato-DXd to standard immunotherapy (pembrolizumab) helps people with advanced or metastatic non-small cell lung cancer live longer without their cancer growing. About 740 adults with a high level of a protein called PD-L1 will be r…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in 72 people with a specific type of advanced lung cancer (HER2-mutant non-small cell lung cancer) that has worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and how safe it …

This study tests whether adding two new drugs (datopotamab deruxtecan and rilvegostomig) after surgery can help prevent early-stage lung cancer from coming back. It is for people with stage I adenocarcinoma non-small cell lung cancer who have signs of cancer DNA in their blood or…

This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. It involves 532 adults with stage IIIB, IIIC, or IV disease who cannot have surgery or radiation. Researchers…

This phase II trial tests a combination of immunotherapy (durvalumab), chemotherapy (carboplatin and paclitaxel), and targeted radiation to metastatic spots, followed by surgery or radiation to the main lung tumor. The goal is to see if this aggressive approach can keep the cance…

This study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that worsened after prior immunotherapy. About 630 adults will receive either the new drug or chemotherapy every 3 weeks for up to…

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…

This phase 2 trial is testing whether giving the targeted drug furmonertinib along with standard chemotherapy before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II to IIIB). Participants take furmonertinib daily for 9 weeks plus th…

This phase 2 study tests two targeted drugs, encorafenib and binimetinib, in 119 people with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the combination can shrink tumors and keep them from growing. Participants take the pill…

This phase 3 trial is comparing an experimental targeted drug called adagrasib (MRTX849) with the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and has already been treated. The study aims to see if adagr…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This phase 2 study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with specific RET gene changes. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and d…

This phase 3 trial tests whether the immunotherapy drug durvalumab can help people with stage III non-small cell lung cancer that hasn't grown after chemoradiation. About 400 participants receive either durvalumab or a placebo every 4 weeks. The goal is to see if durvalumab delay…

This study tests whether adding savolitinib to osimertinib works better than chemotherapy for people with a certain type of advanced lung cancer (EGFR-mutated, MET-positive) that has stopped responding to osimertinib. About 345 adults will be randomly assigned to receive either t…

This study tested whether a combination of two immunotherapy drugs (durvalumab and tremelimumab) works better than standard chemotherapy for people with advanced non-small cell lung cancer. About 950 adults with stage IV lung cancer who had not received prior treatment took part.…

This study tested two immunotherapy drugs (durvalumab and tremelimumab) alone or together against standard chemotherapy for people with advanced non-small cell lung cancer. Over 1,100 adults with no prior treatment took part. The goal was to see if the new treatments helped peopl…

This early-stage trial is testing whether combining three drugs—pembrolizumab, guadecitabine, and mocetinostat—can safely treat advanced non-small cell lung cancer (NSCLC) in people whose cancer has progressed after prior immunotherapy. The study aims to find the safest doses of …

This study tests different treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Participants are grouped by specific genetic markers (biomarkers) to see which therapy works best for their cancer type. The main goal is to see how long …

This clinical trial is testing whether a new investigational drug called JS207, which targets two proteins involved in tumor growth (PD-1 and VEGF), can be safely combined with standard chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC). The st…

This phase 3 study tests whether the targeted drug osimertinib can keep stage III EGFR-mutant lung cancer from progressing after initial chemoradiation. About 216 participants will receive either osimertinib or a placebo daily until their cancer worsens or side effects become una…

This early-phase trial tests whether adding Tumor Treating Fields (TTFields) — a device that delivers electric fields to the tumor — to standard chemoradiation and immunotherapy is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. About …

This study tests whether taking osimertinib for 5 years after surgery can prevent lung cancer from coming back in people with a specific EGFR mutation. About 188 adults with stage II-IIIB non-small cell lung cancer who had their tumor fully removed will take the drug. The main go…

This phase II trial is testing a procedure called bronchial artery chemoembolization (BACE) combined with systemic anti-cancer drugs in people with advanced non-small cell lung cancer who have no standard treatment options left. BACE delivers chemotherapy directly to the blood ve…

This study tests whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy can help control non-small cell lung cancer. About 43 participants will receive the vitamin C alongside their standard therapy. The goal is to see if the combinati…

This study tests a combination of three drugs (chemotherapy, anti-angiogenesis, and immunotherapy) in 30 adults with advanced non-small cell lung cancer that worsened after standard treatments. The goal is to see if this triple therapy is safe and works better than current option…

This phase 2 trial tests whether adding savolitinib to osimertinib can shrink tumors or slow cancer growth in people with a specific type of advanced lung cancer (EGFR-mutated, MET-amplified) that has worsened despite osimertinib treatment. About 30 adults will receive either the…

This study tests whether adding the experimental drug zipalertinib to standard chemotherapy works better than chemotherapy alone for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). About 285 adults who have not had prio…

This trial investigates whether adding the immunotherapy drug pembrolizumab to standard chemotherapy, both before and after surgery, can improve outcomes for people with resectable non-small cell lung cancer. Participants receive either pembrolizumab plus chemotherapy or a placeb…

This Phase 3 trial is testing whether a new drug called volrustomig, combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has spread. The study includes about 1,200 partici…

This phase 2 trial tests whether adding plinabulin to a standard combination of pembrolizumab and docetaxel can shrink tumors or slow disease progression in people with metastatic non-small cell lung cancer that has worsened after prior immunotherapy. About 47 adults with advance…

This early-stage trial is testing a new drug called datopotamab deruxtecan (Dato-DXd) combined with immunotherapy, with or without chemotherapy, in 155 people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and shows signs of shrinking tumo…

This phase 2 trial is testing whether adding an experimental bispecific antibody called JS207—which targets both PD-1 and VEGF—to standard platinum-based chemotherapy can improve outcomes for people with stage II-III non-small cell lung cancer (NSCLC). Participants will receive t…

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…

This trial tests whether precisely targeted radiation (SABR) to a small number of growing tumors, while continuing current drug therapy, can delay overall disease progression in people with metastatic non-small cell lung cancer. About 68 participants whose cancer has started to g…

This study tests a drug called tisotumab vedotin, alone or with other cancer medicines, in people with advanced colorectal, lung, pancreatic, or head and neck cancers that have stopped responding to standard treatments. About 350 participants receive different dosing schedules to…

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…

This study tests whether a shot (subcutaneous injection) of pembrolizumab works as well as the standard IV infusion for people with metastatic non-small cell lung cancer that has high PD-L1 levels. About 67 participants will receive either the shot or IV treatment, and researcher…

This phase 3 trial tests whether adding selumetinib (a targeted therapy) to standard chemotherapy (docetaxel) helps people with advanced KRAS-mutant lung cancer live longer without their cancer growing. About 510 adults whose cancer worsened after first treatment will receive eit…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard radiation therapy helps prevent early-stage non-small cell lung cancer from progressing. It includes about 724 patients who cannot have surgery. A separate group of patients with a specific EGFR…

This phase II trial tests the drug surufatinib, either alone or combined with the chemotherapy vinorelbine, in people with advanced non-small cell lung cancer who have already tried at least two prior treatments. The goal is to see if these treatments can slow tumor growth or shr…

This trial tests whether combining sacituzumab tirumotecan (a targeted antibody-drug conjugate) with anlotinib (a multi-targeted pill) can shrink tumors or slow cancer growth in people with advanced non-squamous non-small cell lung cancer that has no known driver gene mutations. …

This trial tests whether removing the lung tumor before the lymph nodes, or the lymph nodes before the tumor, leads to better long-term survival in people with early-stage non-small cell lung cancer. About 620 patients will be randomly assigned to one of the two sequences. The st…

This study tests a new drug called rilvegostomig (AZD2936) in people with advanced or metastatic non-small cell lung cancer. The drug is designed to boost the immune system's ability to fight cancer by blocking two targets (TIGIT and PD-1). The trial will check for safety, side e…

This study tests whether a new drug combination (ceralasertib plus durvalumab) works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has stopped responding to prior treatments. About 594 participants will be randomly assigned…

This phase 3 trial tests whether a new drug called CT-P51 works as well as the established immunotherapy Keytruda for people with advanced non-squamous non-small cell lung cancer that has not been treated before. All participants also receive standard chemotherapy. The study comp…

This phase II trial is testing whether a combination of surufatinib (a targeted therapy), toripalimab (an immunotherapy), and standard chemotherapy can help people with advanced non-squamous non-small cell lung cancer. The study enrolls adults with stage IIIB or IV disease who ha…

This early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…

This study tests an experimental pill called JS111 in people with advanced non-small cell lung cancer that has specific EGFR mutations. The goal is to see if the drug is safe and can shrink tumors. Participants take the pill once daily, and the trial will determine the best dose …

This Phase 2 trial tests the targeted drug lazertinib, alone or with chemotherapy, before surgery in 160 adults with EGFR-mutant non-small cell lung cancer (stages IB to IIIB). The goal is to see if these treatments can shrink tumors enough to improve surgical outcomes. Participa…

This Phase 3 trial tests whether adding the targeted drug osimertinib to standard chemotherapy can help people with advanced EGFR-mutant non-small cell lung cancer whose disease has progressed after initial osimertinib treatment. About 98 participants will receive either osimerti…

This early-phase trial tests the safety of combining three drugs—osimertinib, a platinum chemotherapy (cisplatin or carboplatin), and etoposide—in people with metastatic EGFR mutant lung cancer that also has changes in the RB1 and TP53 genes. The goal is to find the highest safe …

This phase 3 trial tests whether the targeted drug osimertinib (Tagrisso) can prevent lung cancer from returning in patients with early-stage (IA2-IA3) non-small cell lung cancer that has a specific EGFR mutation. About 390 participants who have had complete tumor removal surgery…

This study tests a combination of two drugs, amivantamab and cetrelimab, in people with advanced non-small cell lung cancer that has spread. The goal is to find the safest dose and see if the combo can shrink tumors. About 71 participants will take part in this early-stage trial.

This early-phase trial is testing two experimental drugs, lazertinib and amivantamab, alone or together, in 701 people with advanced non-small cell lung cancer. The goal is to find safe doses and see if the combination can shrink tumors. Participants have already tried standard t…

This study tests if a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus chemotherapy works better than the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-small cell lung cancer that has spread. The trial is for patien…

This phase 2/3 trial is testing whether adding two immunotherapy drugs (cobolimab and dostarlimab) to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. The study includes about 758 participants whose cancer has worsened after pri…

This phase 2 trial tests a combination of three drugs—daratumumab, a KRAS vaccine, and nivolumab—in people with advanced pancreatic cancer or non-small cell lung cancer that has not responded to prior treatment. The goal is to see if the combination can shrink tumors or slow canc…

This study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…

This phase 3 trial tests whether a daily inhaler containing two bronchodilators (vilanterol and umeclidinium) can help preserve lung function and improve quality of life in people with mild-to-moderate COPD who are undergoing lung cancer surgery. About 204 participants will use t…

This early-phase trial tests whether adding the experimental drug binimetinib to the immunotherapy pembrolizumab (Keytruda) helps people with advanced non-small cell lung cancer. The study includes 40 participants whose tumors have high PD-L1 levels. Researchers are looking at sa…

This phase 2 trial tests whether continuing the immunotherapy drug cemiplimab for up to a year after initial treatment can delay cancer growth in people with stage IV non-small cell lung cancer that has spread to only a few places (oligometastatic). About 136 participants will be…

This phase II trial investigates whether adding two immunotherapy drugs—tiragolumab and atezolizumab—to standard chemotherapy before and after surgery can improve outcomes for people with resectable non-small cell lung cancer. The study enrolls 35 adults with stage II to IIIB dis…

This trial aimed to test a new treatment for advanced lung cancer using specially grown immune cells (LC-CTLs) designed to attack cancer. The study was withdrawn before enrolling any participants, so no results are available. It was planned as an early safety and lab-effectivenes…

This phase 2 trial tests whether combining the targeted drug adagrasib with immunotherapy (pembrolizumab) and chemotherapy can shrink tumors or delay progression in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study enrolls adults wh…

This phase II trial tests whether adding ivonescimab (an immunotherapy drug) to the current targeted therapy pill can help people with advanced non-small cell lung cancer whose disease is slowly progressing. The study involves 36 adults with a specific EGFR gene mutation. Researc…

This study tests an experimental drug called NEO-201 combined with the immunotherapy pembrolizumab in adults with advanced solid tumors that no longer respond to chemotherapy. The trial focuses on lung, head and neck, cervical, and uterine cancers. Researchers aim to find a safe …

This study offers continued access to the cancer drug avelumab (and sometimes other drugs) for people with advanced cancers like lung, ovarian, or bladder cancer who are already seeing benefits from a previous Pfizer-sponsored trial. About 77 participants will be followed for saf…

This study tests whether adding an experimental drug called nogapendekin alfa inbakicept (NAI) to standard chemotherapy and immunotherapy can help people with advanced non-small cell lung cancer live longer without their cancer growing. About 494 adults with stage IV lung cancer …

This phase 2 trial tests whether combining sacituzumab govitecan (a targeted antibody-drug conjugate) with pembrolizumab (an immunotherapy) before and after surgery can improve outcomes for people with resectable non-small cell lung cancer (NSCLC). Participants receive four cycle…

This Phase III trial tests whether adding oleclumab or monalizumab to the standard drug durvalumab can help people with stage III non-small cell lung cancer that hasn't worsened after chemoradiation. About 1,050 participants will receive one of the combinations or a placebo. The …

This study tests an experimental drug called CLN-081 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already received chemotherapy. The goal is to see if the drug is safe and can shrink tumors.

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This study tests a new drug called JDQ443, which targets a specific cancer-driving mutation (KRAS G12C), in combination with other drugs (trametinib, ribociclib, or cetuximab). The trial enrolls about 74 people with advanced solid tumors (like lung or colorectal cancer) that have…

This phase 3 trial tests an experimental drug called SY-5007 in people with advanced non-small cell lung cancer that has a specific genetic change (RET fusion). The drug is a daily pill designed to block the cancer-driving RET protein. The study aims to see how well the drug shri…

This early study tests a new device that uses electric pulses to destroy malignant lung nodules in people with early-stage lung cancer or limited lung metastases. Five participants will undergo a procedure where a needle is guided into the tumor using CT scans, then delivers elec…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This trial is testing a combination of the immunotherapy drug tislelizumab plus two chemotherapy drugs (albumin-bound paclitaxel and a platinum agent) in 30 people with a specific type of lung cancer called KRAS-mutant non-small cell lung cancer. The participants have advanced or…

This study compares two types of radiation therapy (proton and photon) combined with chemotherapy for people with stage II-IIIB non-small cell lung cancer that cannot be surgically removed. The goal is to see which approach helps patients live longer and causes fewer side effects…

This study tests whether two immunotherapy drugs, balstilimab and botensilimab, are safe and effective as a first treatment for people with metastatic non-small cell lung cancer. The trial includes 45 participants who have not had prior treatment for advanced disease. Researchers…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This study is testing several immunotherapy drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations can shrink tumors and improve survival. About 400 participants will receive different drug mixes, including d…

This study looks at how well a combination of two immunotherapy drugs (nivolumab and ipilimumab), with or without chemotherapy, works as a first treatment for advanced or recurrent non-small cell lung cancer in Japan. Researchers will track about 525 patients to measure survival,…

This phase 2 study tests several new drug combinations in people with non-small-cell lung cancer. It includes three substudies: one for untreated advanced cancer, one for cancer that has progressed after prior treatment, and one for early-stage cancer that can be surgically remov…

This study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…

This study tests a new drug called anvumetostat, alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that lack the MTAP gene. The goal is to find the safest dose and see if it shrinks tumors. About 329 people will take part across multiple phases.

This study tests whether using a sensitive blood test (MRD) to guide follow-up treatment can improve outcomes for people with a specific type of advanced lung cancer (EGFR-mutant stage III NSCLC). Participants first receive a targeted pill (aumolertinib), then a team of doctors d…

This study tests a new drug called PLB1004 in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors and how safe it is. About 139 adults who have already tried oth…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to a standard three-drug chemotherapy regimen (carboplatin, pemetrexed, and bevacizumab) helps people with advanced non-squamous lung cancer live longer without their disease worsening. The study enrolls …

This study tests whether the immunotherapy drug nivolumab, alone or with chemotherapy, can shrink early-stage non-small cell lung cancer before surgery and help prevent it from coming back after surgery. About 316 people with stage II or IIIA lung cancer that can be removed will …

This early-phase trial is testing whether adding the immunotherapy drug ipilimumab (Yervoy) to the targeted therapy osimertinib (Tagrisso) is safe and tolerable for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study involves 2…

This study tests whether adding an experimental drug (N-803) to the immunotherapy pembrolizumab can help control advanced non-small cell lung cancer better than standard treatments. The drug combo aims to activate natural killer cells and boost the immune system's attack on cance…

This study tests whether giving the immunotherapy drug pembrolizumab every 12 weeks works as well as the standard every 3 weeks in people with non-small cell lung cancer who are already benefiting from the drug. The goal is to see if fewer treatments can keep the cancer under con…

This study tests an oral drug called mobocertinib in Japanese adults with non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the drug shrinks tumors. About 53 people will take the drug daily for up to a year or longer if their cancer s…

This phase 2 trial tests two drugs, durvalumab and oleclumab, given together after standard chemoradiation in 30 people with stage III lung cancer that cannot be removed by surgery. The goal is to see if the combination can delay cancer progression. Participants must have stable …

This study tests two different schedules of a subcutaneous (under-the-skin) form of the immunotherapy drug nivolumab, given together with intravenous ipilimumab and chemotherapy. It includes 76 adults with advanced or recurrent non-small cell lung cancer who have not had prior tr…

This early-stage trial tests a new drug called YL202 in about 80 people with advanced lung or breast cancer that has not responded to standard treatments. The drug is given by IV every three weeks. The main goal is to check safety and find the right dose, not yet to prove it work…

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This study tests whether adding the drugs pembrolizumab and olaparib to standard chemoradiation helps people with stage III non-small cell lung cancer live longer without their cancer growing. About 870 participants will receive one of three treatments: pembrolizumab with chemora…

This study was designed to test the safety and effectiveness of ningetinib in people with advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. The trial planned to enroll adults aged 18-75 with stage IIIB-IV cancer. However, the stud…

This early-stage trial is testing a combination of two drugs—datopotamab deruxtecan (Dato-DXd) and pembrolizumab (Keytruda)—with or without standard chemotherapy in people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumor…

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This early-phase trial tests whether adding low-dose radiation and targeted radiation (SBRT) to an immunotherapy drug (PD-1 inhibitor) is safe for people with stage IV non-small cell lung cancer who have not responded to standard treatments. About 9 participants will receive the …

This early-stage trial tests whether combining the immunotherapy durvalumab with other experimental drugs (danvatirsen, oleclumab) and/or chemotherapy can safely control stage IV non-small cell lung cancer. About 175 people who have not had prior treatment for metastatic disease …

This early-phase study tests a new type of immune cell therapy (universal CAR-T) in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also measuring how well the the…

This phase 3 trial compares a new targeted drug, sacituzumab govitecan, against the standard chemotherapy docetaxel in 603 people with advanced non-small cell lung cancer that has worsened after prior treatments. The main goal is to see if the new drug helps people live longer. T…

This phase 2 trial is testing whether combining two drugs, ensartinib and bevacizumab, can help people with advanced lung cancer that has both an ALK rearrangement and a TP53 mutation. The study includes 47 participants who take ensartinib daily and receive bevacizumab every thre…

This Phase III trial tests whether adding immunotherapy to standard chemotherapy after lung cancer surgery can delay or prevent the cancer from coming back. It enrolls 210 patients with stage IB-IIIA non-small cell lung cancer that was completely removed. Participants are randoml…

This phase 2 trial tests giving chemotherapy (carboplatin and paclitaxel) plus the immunotherapy drug nivolumab before surgery for people with Pancoast tumors, a rare type of lung cancer. After surgery, additional treatment is tailored based on whether the tumor was fully removed…

This study tests whether a single, powerful dose of targeted radiation (SBRT) can safely control central non-small cell lung cancer, instead of the usual multiple sessions. About 30 adults with early-stage tumors near the chest center will receive one treatment. Researchers will …

This phase II trial tests whether adding stereotactic ablative radiotherapy (SABR) to standard anti-cancer therapy improves survival for people with non-small cell lung cancer that has spread to only a few spots (oligometastatic). About 140 participants are randomly assigned to r…

This phase 2 trial is testing a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two cycles of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The study aims to see if this approach can control the cancer …

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…

This phase 2 trial tests whether adding an mRNA vaccine (BNT116) to standard immunotherapy (cemiplimab) works better than immunotherapy alone for people with advanced non-small cell lung cancer. About 51 patients whose tumors have high PD-L1 levels will receive either the combina…

This phase 2 study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese patients with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the drugs can shrink tumors and control the disease. About 63 pat…

This phase II trial tests whether adding immunotherapy to standard chemotherapy before surgery helps eliminate more lung cancer in patients with advanced, but potentially removable, non-small cell lung cancer. 90 participants will be randomly assigned to receive either chemo-immu…

This study tested a drug called sacituzumab govitecan in 227 people whose solid tumors had spread to other parts of the body. The main goal was to see if the drug could shrink tumors. Researchers measured how many patients had their tumors shrink or disappear. This is not a cure,…

This study aimed to compare three different immunotherapy drug regimens given before and after surgery for people with early-stage non-small-cell lung cancer. The goal was to see which approach best prevented the cancer from coming back. However, the trial was withdrawn before en…

This study tests a two-step treatment for people with a specific type of lung cancer (EGFR-mutant, stage II-IIIB). First, patients take a targeted pill (almonertinib), then receive a combination of immunotherapy (adebrelimab) and chemotherapy. After these treatments, they have su…

This early-phase trial tests two drugs, tepotinib and pembrolizumab, together in 19 people with advanced non-small cell lung cancer. Tepotinib targets a specific gene change (MET) that can help cancer grow, while pembrolizumab boosts the immune system. The goal is to see if this …

This Phase 3 study is testing whether a combination of three drugs—datopotamab deruxtecan (Dato-DXd), durvalumab, and carboplatin—works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that does not h…

This study tests a new drug called PLB1004 against standard chemotherapy for people with advanced non-small-cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). About 327 adults with this cancer type will be randomly assigned to receive either PLB1004 or …

This phase 2 study tests whether adding savolitinib to osimertinib can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to osimertinib alone. About 367 participants will receive the drug…

This study tests a combination of three drugs—bevacizumab, nab-paclitaxel, and a platinum drug—as a second-line treatment for people with advanced non-squamous non-small cell lung cancer that does not have certain genetic mutations. The cancer must have worsened after first-line …

This phase 3 trial tests whether a combination of two drugs—ramucirumab (which blocks blood vessel growth to tumors) and pembrolizumab (which boosts the immune system)—works better than standard chemotherapy for people with advanced or recurrent non-small cell lung cancer that ha…

This Phase 3 trial compares a new drug called BL-B01D1 to the standard chemo docetaxel in 698 people with advanced non-small cell lung cancer that has not responded to prior immunotherapy and chemo. The goal is to see if BL-B01D1 helps people live longer. Participants receive eit…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This study looks at using radiofrequency ablation (RFA) — a procedure that uses heat to destroy tumors — to treat lung cancer or tumors that have spread to the lungs. It is for patients who cannot have surgery due to other health issues. The goal is to see if RFA can control tumo…

This study tests the drug lorlatinib in people with a specific type of lung cancer (ALK-positive) that has spread to the brain or the lining of the brain and spinal cord. The goal is to see how well the drug shrinks these brain tumors. About 41 participants will take lorlatinib o…

This study was designed to test a new combination of drugs for people with advanced non-small cell lung cancer. The goal was to see if the treatment was safe and could shrink tumors. However, the trial was withdrawn before any participants were enrolled, so no results are availab…

This early-phase trial tests two experimental vaccines (ChAdOx1 and MVA) designed to help the immune system target cancer proteins MAGE-A3 and NY-ESO-1. About 15 adults with advanced non-small cell lung cancer or squamous esophageal cancer will receive the vaccines alongside thei…

This phase 2 study is testing whether giving the immune-boosting drug cemiplimab (alone or with other drugs) before surgery can shrink tumors in people with non-small cell lung cancer, liver cancer, or head and neck cancer. About 65 participants will receive treatment before thei…

This study tests whether adding a special type of radiation to standard immunotherapy before surgery can help prevent lung cancer from coming back. About 90 people with stage III lung cancer that has spread to lymph nodes will receive chemotherapy, then immunotherapy plus radiati…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This study tests whether ABP 234, a biosimilar to the cancer drug Keytruda, works the same in people with early-stage non-squamous lung cancer after surgery and chemotherapy. About 163 adults will receive either ABP 234 or Keytruda to compare how the drug behaves in the body. The…

This study tests whether giving the targeted drug osimertinib before surgery can shrink tumors in people with early-stage EGFR-mutant non-small cell lung cancer. About 27 adults with stage I to IIIA disease will receive the drug before their operation. The main goal is to see how…

This phase 3 trial compares a new oral targeted drug, TAK-788 (mobocertinib), against standard chemotherapy as a first treatment for advanced non-small cell lung cancer with a specific EGFR mutation (exon 20 insertion). About 354 adults with this rare mutation will be randomly as…

This study looks at using a targeted drug called osimertinib together with precise brain radiation as the first treatment for people with a certain type of lung cancer (EGFR-mutant) that has spread to the brain and causes symptoms. Researchers reviewed medical records of 300 pati…

This study was designed to test a new oral drug called IN10018 combined with chemotherapy (nab-paclitaxel) and an immunotherapy (tislelizumab) in people with advanced solid tumors, specifically non-small cell lung cancer, that had stopped responding to prior treatments. The goal …

This early-phase trial is testing an experimental oral drug called ANS014004 in 40 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, then expanding to see if the drug can shrink tumors. The m…

This phase II trial tests the drug selpercatinib (LOXO-292) in 124 people with stage IV or recurrent non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug works by blocking enzymes that help cancer cells grow. Researchers are measuring how ma…

This study was designed to test two immunotherapy drugs, atezolizumab and tiragolumab, in people with advanced lung cancer that has special immune cell clusters called tertiary lymphoid structures. The trial was withdrawn before enrolling any participants, so no results are avail…

This study tests a new drug called JDQ443, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the safest dose and see if the drug can shrink tumors. About 344 adults whose cancer has not …

This study tested whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) to standard chemotherapy helps people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 1,186 adults with metastatic NSCLC who had not re…

This study tests an experimental drug, YL201, in about 990 people with advanced solid tumors like lung, prostate, and liver cancers. The goal is to check safety and see if tumors shrink. It is an early-stage trial, so the drug is not yet proven to work.

This phase 2 trial tests whether a combination of two immunotherapy drugs (ipilimumab and cemiplimab) plus targeted radiation can help people with advanced non-small cell lung cancer whose previous immunotherapy stopped working. The study enrolls 54 participants and aims to see i…

This phase 1/2 trial tests a vaccine made from two viruses designed to target and kill cancer cells that have a specific protein called MAGE-A3. The viruses are given to 56 people with advanced solid tumours that have not responded to other treatments. The goal is to see if the v…

This study tests two different chemotherapy plus immunotherapy combinations in people with advanced lung cancer that has a specific marker (TTF-1 negative). About 136 participants will be randomly assigned to one of two treatment groups. The goal is to see which combination helps…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This early-stage trial is for people with stage IV non-small cell lung cancer. It tests whether giving targeted radiation before or at the same time as two immunotherapy drugs (nivolumab and ipilimumab) is safe. The goal is to find the best radiation dose for different tumor loca…

This study tests a text-message chatbot called 'Penny' that sends reminders and checks in on symptoms for lung cancer patients taking daily targeted therapy pills. 75 patients will either use the chatbot or get usual care, and researchers will measure how well they stick to their…

This study tests whether the drug selpercatinib can delay the return of lung cancer in people with early-stage non-small cell lung cancer that has a specific genetic change (RET fusion). Participants have already had surgery or radiation to remove or treat their cancer. They will…

This phase 2 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy and radiation can help people with large, locally advanced non-small cell lung cancer. About 50 participants will receive two cycles of toripalimab plus chemo, followed by chemorad…

This early-stage trial is testing whether a combination of two drugs, naporafenib and trametinib, can shrink or control advanced solid tumors that have a specific genetic change called RAS Q61X. About 86 people whose cancer has not responded to standard treatments will receive th…

This Phase 3 trial tests whether adding radiation to the standard combination of pembrolizumab (an immunotherapy) and chemotherapy can improve survival in people with advanced non-small cell lung cancer. About 327 participants with stage IIIB/IV disease will receive either the tr…

This early-phase trial planned to test a new approach for people with metastatic non-small cell lung cancer. Doctors would remove immune cells from the tumor, edit them with CRISPR to remove a gene called CISH, and then infuse them back to help fight the cancer. However, the tria…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This Phase 2 trial tests a genetically modified herpes virus (RP1) alone or with the immunotherapy drug nivolumab in people with advanced solid tumors, including melanoma, non-small cell lung cancer, and certain skin cancers. The study aims to see if the combination is safe and c…

This phase 2 trial tests the drug T-DXd (Enhertu) in 27 adults with advanced HER2-mutant lung cancer that has spread to the brain but is not causing symptoms. The main goal is to see how long the drug can keep brain tumors from growing. T-DXd is already approved for certain lung …

This Phase 2 trial compares the drug atezolizumab alone versus atezolizumab plus bevacizumab as a first treatment for people with advanced non-small-cell lung cancer that has a specific marker (PD-L1). About 206 patients are taking part. The main goal is to see if the combination…

This phase 3 study tests whether the targeted drug abemaciclib can help people with stage IV lung cancer that has a KRAS mutation and has worsened after chemotherapy. About 450 participants received either abemaciclib or another targeted drug (erlotinib), both alongside best supp…

This study tests two drug combinations (Tedopi plus docetaxel or Tedopi plus nivolumab) in people with advanced non-small-cell lung cancer whose disease worsened after initial chemo-immunotherapy. About 105 participants with a specific genetic marker (HLA-A2+) will receive one of…

This study looks at whether a blood test (liquid biopsy) can help doctors see how well the drug brigatinib is working in people with a certain type of advanced lung cancer (ALK-positive NSCLC). About 33 patients who have not had chemotherapy before will take brigatinib pills dail…

This study tests whether a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has not been treated…

This phase 2 trial tests a combination of lazertinib (a targeted pill) plus two chemotherapy drugs (pemetrexed and carboplatin) in 87 adults with a specific type of advanced lung cancer (EGFR mutation-positive non-small cell lung cancer) that has stopped responding to lazertinib …

This phase II trial tests whether adding two drugs (amivantamab and bevacizumab) to the targeted therapy lazertinib can shrink tumors in 60 people with advanced EGFR-mutant non-small cell lung cancer whose disease progressed on a prior targeted therapy. The main goal is to see ho…

This Phase 3 trial tests whether adding ramucirumab (a drug that blocks blood vessel growth) to the standard targeted therapy erlotinib can help people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) live longer without their cancer getting worse. About 545 peop…

This phase 2 trial is testing whether it is safe and effective to continue the targeted therapy osimertinib while also giving radiation to areas where lung cancer has started to grow again. The study includes 42 adults with EGFR-positive non-small cell lung cancer who are already…

This trial tests a new drug called roginolisib combined with two other drugs (dostarlimab and docetaxel) in 45 adults with advanced non-squamous lung cancer that has worsened after standard treatments. The main goals are to see if the combo is safe and whether it reduces certain …

This study tests whether combining two or three drugs can help people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C). The drugs aim to block cancer growth signals. About 153 adults who have or haven't received prior KRAS-targeting therapy will take part…

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…

This program provides taletrectinib, a targeted cancer pill, to adults with advanced or metastatic ROS1-positive non-small cell lung cancer who cannot join a clinical trial or use approved treatments. Patients must have a ROS1 gene fusion and adequate organ function. The goal is …

This early-phase trial tests a personalized vaccine called Microlyvaq™ for people with advanced non-small cell lung cancer. The vaccine is custom-made for each patient using AI and quantum modeling to target their unique tumor mutations. It is given alongside standard chemotherap…

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…

This study tests a new drug called DS-1062a in 100 people with advanced non-small cell lung cancer that has worsened after standard treatments. The drug is given every three weeks and aims to shrink tumors. Researchers will also study how the drug affects the immune system and lo…

This early-stage trial tests a new drug called CLN-619, which targets specific proteins on cancer cells to help the immune system fight tumors. It is being tested alone or with another drug (pembrolizumab) in about 440 adults with advanced solid tumors that have spread. The main …

This phase 2 study tests whether adding chemotherapy to the targeted drug brigatinib helps people with advanced ALK-positive non-small cell lung cancer live longer without their cancer growing. About 110 people who have not had treatment for advanced disease will receive either b…

This study looks at whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps elderly patients (70+) with advanced non-small cell lung cancer live longer. About 510 participants will receive either chemotherapy alone or chemotherapy plus atezolizumab. The …

This study tests whether adding an immunotherapy drug (atezolizumab) to a standard two-drug chemotherapy (paclitaxel and bevacizumab) can help people with advanced non-squamous lung cancer whose disease has worsened after prior immunotherapy and chemotherapy. About 156 participan…

This study is for people with advanced non-small cell lung cancer whose disease got worse after treatment with immunotherapy (anti-PD-1/PD-L1 drugs). It tests several different drug combinations, chosen based on the unique markers (biomarkers) in each person's tumor. The goal is …

This study tests a drug called selpercatinib against standard chemotherapy for people with a certain type of advanced lung cancer (RET fusion-positive non-small cell lung cancer). The goal is to see if selpercatinib can delay cancer growth better than current treatments. About 26…

This phase 3 trial compares the standard drug osimertinib alone versus osimertinib combined with two chemotherapy drugs (carboplatin and pemetrexed) as a first treatment for people with advanced non-squamous lung cancer that has both EGFR and TP53 mutations. The study involves 29…

This early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…

This early-phase study tests a new way to give immunotherapy drugs (nivolumab and ipilimumab) for patients with lung cancer or melanoma that has spread to the lining of the brain and spinal cord (leptomeningeal metastases). The drugs are given both directly into the spinal fluid …

This trial tests whether giving a higher radiation dose to the most active parts of a lung tumor can better control the cancer. About 78 people with locally advanced non-small cell lung cancer will receive either standard chemoradiation or chemoradiation with an extra radiation b…

This French phase 3 trial compares pembrolizumab alone versus pembrolizumab plus chemotherapy as a first treatment for advanced non-small-cell lung cancer with high PDL1 levels (50% or more). About 349 participants are enrolled. The goal is to see if the combination reduces early…

This phase II trial tests a precise type of radiation called SABR in 39 people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). The goal is to see if this treatment can control the cancer while keeping side effects manageable. P…

This study planned to test a targeted cancer pill (adagrasib) alone or with an immunotherapy drug (nivolumab) before surgery in people with a specific type of lung cancer (KRAS G12C mutation). The goal was to see if these drugs could eliminate all cancer cells by the time of surg…

This study was designed to test a combination of chemotherapy drugs (cisplatin and docetaxel) with radiation therapy for people with advanced non-small cell lung cancer that could not be removed by surgery. The plan included chemotherapy before, during, and after radiation. Howev…

This study was designed to test a combination of two drugs, Ezabenlimab and BI907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the treatment could control the disease for at least 24 weeks. However, the trial was wi…

This early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …

This trial tests whether a blood test that detects circulating tumor DNA (ctDNA) can predict when advanced non-small cell lung cancer might progress in people who have already benefited from first-line immunotherapy for at least 12 months. Researchers will follow 100 participants…

This study tests a new PET imaging tracer called [18F]F-AraG to see if it can spot activated T-cells inside non-small cell lung cancer tumors. Researchers will scan about 10 patients with resectable lung cancer, then compare the tracer's uptake with lab analysis of the removed tu…

This study is testing a blood-based genetic test to find cancer-driving mutations in patients with lung cancer or melanoma. The goal is to see if this simple blood draw can replace the need for a tumor biopsy, which is slower and more invasive. Researchers will check how accurate…

This study looks at whether fluid washed from inside a lung tumor can be used to find genetic changes in early-stage lung cancer. About 50 adults with suspected resectable lung cancer will have a special bronchoscopy to collect this fluid. The goal is to see if this method is as …

This study looks at a new lab technique called OSNA that may find tiny amounts of cancer in lymph nodes better than current methods. About 130 people with early-stage lung cancer having robotic surgery will take part. Half will have their lymph nodes checked with OSNA, the other …

This study tests whether a liquid biopsy (a blood test that looks for cancer DNA) can help doctors decide on treatment for advanced lung cancer faster than the usual method of testing tumor tissue. About 170 newly diagnosed patients will receive both the blood test and standard t…

This study is testing whether a blood test called Nodify XL2 can help doctors decide how to manage lung nodules that have a low to moderate chance of being cancer. About 2,000 adults with solid lung nodules between 8 and 30 mm are taking part. The goal is to see if using the test…

Researchers are testing whether a 14-gene test can identify people with early-stage non-squamous non-small cell lung cancer who are at higher risk of the cancer returning after surgery. Patients whose tumors are completely removed and who test as intermediate or high risk are ran…

This study was designed to test whether an oral drug called SPI-1005 could prevent hearing loss and ringing in the ears caused by platinum-based chemotherapy. It was planned for adults with advanced lung or head and neck cancer. The study was withdrawn before enrolling any partic…

This study tests a 6-week mindfulness-based program for lung cancer patients struggling with breathlessness, cough, and fatigue. The program combines mindful breathing, relaxation, cough control, acupressure, and light exercise. Researchers will check if it's practical and liked …

This study tests a new web-based tool called CONNECT, designed to help caregivers of people with stage II to IV lung cancer find support resources. About 216 caregivers will use the tool and have sessions with a navigator to see if it helps them feel more supported. The goal is t…

This early-stage study tests whether giving a single, very focused dose of radiation after lung cancer surgery is safe and causes fewer side effects than standard weeks-long radiation. It involves 50 adults with non-small cell lung cancer who had surgery but still have cancer cel…

This pilot study tests the drug ruxolitinib in people with advanced non-small cell lung cancer who are experiencing cancer cachexia—unintended weight loss and muscle wasting. The main goal is to check for side effects and see how the drug affects body signals related to appetite …

This study looks at whether starting rehabilitation early or later helps reduce cancer-related fatigue in people with lung cancer. About 31 patients with stage II or III lung cancer will take part. The goal is to see if the rehab program is practical and helpful for improving ene…

This study tested a shorter course of high-dose radiation for people with stage IV lung cancer. The goal was to see if giving fewer, larger doses over fewer days could be as safe and effective as the standard longer schedule. 37 participants received radiation every other day for…

This phase 2 study looks at whether people with certain cancers (non-small cell lung cancer, kidney cancer, or melanoma) prefer getting the drug pembrolizumab as a quick shot under the skin instead of a longer IV infusion. About 147 participants will try both methods and then say…

This study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…

This study tests whether a few counseling sessions can improve quality of life for adults who have just finished lung cancer treatment with the goal of cure. One group gets five sessions focused on coping skills and social support; the other gets one session with referrals. Resea…

This study tests a new support program for adults with lung cancer or mesothelioma who have finished treatment. The goal is to help them improve their quality of life as they move from active treatment to regular check-ups. About 21 participants will try the program to see if it …

This study aimed to see if a newer, daily-adaptive radiation technique could reduce coughing, breathing trouble, and swallowing pain in people with stage III non-small cell lung cancer getting chemo and radiation. It planned to compare the adaptive method to standard radiation. H…

This study tested whether a procedure called extracorporeal photopheresis (ECP) could help people with melanoma or lung cancer who have severe diarrhea and colon inflammation from immunotherapy drugs. ECP involves taking blood, treating white blood cells with a light-activated dr…

Researchers are building a large bank of blood and stool samples from people with advanced lung, breast, colorectal, and pancreatic cancers, plus healthy volunteers. The goal is to learn whether the mix of bacteria in a person's gut can predict how well cancer treatment works and…

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

Researchers are building a bank of blood, urine, and stool samples from 100 adults with non-small-cell lung or colorectal cancer who are receiving checkpoint inhibitor immunotherapy. Over 12 months, participants provide five samples of each type. The goal is to study how the body…

This study looks at how patients with ALK-positive advanced non-small cell lung cancer respond to the drug lorlatinib when used as their first treatment in real-world settings. Researchers will analyze data from 200 patients in a U.S. database to see how long they stay on the dru…

This study looks at whether new AI tools can make adaptive radiotherapy—adjusting radiation plans during treatment—faster and easier for people with advanced lung cancer. Researchers will measure how long each step takes and compare plan quality using standard CT scans versus dai…

This study will look back at medical records of about 1,000 people in the US with advanced non-small cell lung cancer who received a combination of the drug cemiplimab and chemotherapy as their first treatment. Researchers want to see how well the treatment works and what side ef…

This study is watching how patients with EGFR-mutated non-small cell lung cancer do when they receive standard treatment with osimertinib (Tagrisso) alone or with chemotherapy in routine medical practice. About 538 people with advanced lung cancer will be followed to see how long…

This large study (ALCHEMIST) is screening over 8,000 people with early-stage non-small cell lung cancer to analyze the genes in their tumors. The goal is to identify genetic changes that could help doctors choose the best treatments, such as targeted therapies. Participants provi…

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This study looks at how tiny genetic differences (called SNPs) in ALK-positive non-small cell lung cancer patients might influence how well the drug alectinib works and what side effects occur. Researchers will analyze DNA from 600 patients who have been taking alectinib for at l…

This study looks back at medical records of 50 Chinese adults with advanced ALK-positive non-small cell lung cancer who received lorlatinib as their first treatment. Researchers want to learn about patient characteristics, such as age and smoking history, and how the drug is used…

This trial investigates whether comprehensive genomic analysis of tumor tissue can help doctors choose targeted therapies for patients with advanced non-small cell lung cancer. Participants provide tumor samples (from past biopsies or new ones) for genetic testing. The goal is to…

This study is testing whether regular blood tests that look for tumor DNA (called liquid biopsy) can help doctors make better treatment decisions for people with advanced colorectal or lung cancer. About 332 participants will be randomly assigned to either receive standard imagin…

This study looks at medical records from Europe and Canada to understand how immunotherapy is used in people with non-small cell lung cancer who have had surgery. It tracks patient characteristics, treatments before and after surgery, and outcomes like survival and complications.…

This study examines whether changes in the LKB1 gene can help predict how well people with non-small cell lung cancer respond to treatments like chemotherapy, targeted therapy, and immunotherapy. Researchers will analyze tumor samples and medical records from about 300 patients t…

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…

This study follows about 800 people with ALK-positive advanced non-small cell lung cancer who are taking the drug alectinib as part of their routine care. Researchers want to see how long the cancer stays under control and how patients are managed in real-world clinics, not just …

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This study collects extra tissue samples from 200 people with advanced non-small cell lung cancer during routine biopsies. The goal is to train and validate a new diagnostic platform called Cybrid, which aims to predict how well a patient's tumor will respond to immunotherapy. Th…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study follows 305 people with stage III non-small cell lung cancer who have specific genetic mutations. Researchers regularly test their blood for tiny traces of cancer DNA (minimal residual disease, or MRD) to see if it can predict when the cancer will come back. The goal i…

This study observes how doctors in Russia treat inoperable lung cancer (NSCLC and SCLC) using chemoradiotherapy. Researchers will collect data from 2000 patients across 50 cancer centers to understand real-world practices and short-term outcomes. No new treatments are given; the …

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study looks at whether a custom blood test, based on each patient's tumor DNA, can detect if early-stage non-small cell lung cancer comes back after surgery. Researchers will follow 450 patients and compare the test's timing with standard imaging like CT scans. The goal is t…

This study follows over 1,000 people with newly diagnosed non-small cell lung cancer in community cancer clinics. Researchers want to see how many patients receive key biomarker test results before starting treatment, and what barriers (like tissue issues or insurance problems) c…

This study looks at medical records from 770 people with advanced lung cancer to see if real-world data can produce the same results as a previous clinical trial (KEYNOTE-042). The goal is to learn when and how to trust real-world data for future research. No new treatments are g…

This study follows over 1,800 adults who had early-stage lung cancer treatment to see how often they get CT scans and whether scanning every 6 months helps them live longer than yearly scans. Researchers will also check if scan frequency differs by race, income, or location. The …

This study collects and analyzes lung cancer tissue samples from 500 patients in Asia to find out which genetic changes are most common. The goal is to better understand the disease in the local population. Participants must have a tissue sample available and be healthy enough fo…

This study looks at whether information from electronic health records can be used to recreate the results of two earlier clinical trials (CheckMate 017 and 057) for advanced lung cancer. Researchers will compare survival outcomes in patients who started either nivolumab or docet…

This study follows 814 people with early-stage non-small cell lung cancer to understand how the cancer evolves and spreads. Researchers collect tumor samples and medical data to see how genetic changes relate to treatment outcomes. The goal is to find ways to reduce the chance of…

This study looks at whether the size and shape of the thymus gland, along with the radiation dose it receives, can predict a drop in immune cells (lymphocytes) during chest radiation for stage III lung cancer. Researchers will collect data from standard scans and blood tests of 4…

This study looks at CT scans and other data from 2000 lung cancer patients to build a tool that predicts if the cancer will come back after surgery. The goal is to help doctors decide who needs closer monitoring. It is a retrospective study, meaning it analyzes past information r…

This study looks at why some lung cancers stop responding to the drug osimertinib. Researchers will analyze the genetic makeup of tumors from 148 patients with advanced EGFR-mutant lung cancer who take osimertinib as their first treatment. The goal is to identify resistance mecha…

This study compares two robotic platforms, DaVinci Xi and Versius, used in lung surgery to remove tumors or nodules. Researchers want to see if one leads to better recovery, fewer complications, or lower costs. About 150 patients having robotic lung surgery will answer quality-of…

This study follows 330 people with non-small cell lung cancer who receive immunotherapy before surgery. Researchers measure cortisol levels at different times to see if changes in this stress hormone relate to how well the tumor shrinks or if side effects occur. The goal is to fi…

This study follows 50 adults with ALK-positive non-small cell lung cancer who are taking brigatinib as their first treatment. Researchers want to see how long the cancer stays under control and how many patients respond to the drug in everyday hospital settings. No new treatment …

This study asks 50 lung cancer doctors to review AI-generated explanations for patient prognosis and rate how trustworthy they seem. The goal is to see if a newer type of AI (neurosymbolic) is more trusted than standard methods. No patients are treated; the data is simulated. The…

This study follows 446 people with stage I non-small cell lung cancer who chose either surgery or stereotactic body radiation therapy (SBRT). Researchers will track cancer recurrence, survival, and quality of life for up to 3 years to see which treatment offers better outcomes. T…

This study aims to collect medical history and tissue or saliva samples from 100 people with a specific type of advanced lung cancer called ALK+ non-small cell lung cancer. Researchers will analyze these samples to better understand the genetic and immune features of the disease.…

This study looks at the bacteria living in the gut, lungs, and airways of 40 people with non-small cell lung cancer. Half receive surgery only, and half get chemotherapy before surgery. Researchers collect samples like blood, saliva, stool, and lung tissue to see how these bacter…

This study follows 250 adults in Russia with advanced, inoperable non-small cell lung cancer who are receiving durvalumab after chemoradiation. Researchers will track side effects, treatment duration, and outcomes to see how the drug performs in routine clinical practice. The goa…

This study tests whether an electronic health record reminder (a 'nudge') can prompt doctors to order genetic tests for patients newly diagnosed with advanced non-small cell lung cancer. The goal is to have test results available before starting treatment, so doctors can choose t…

This early study tests whether using real-time MRI to guide radiation therapy is possible for people with advanced non-small cell lung cancer. The goal is to see if this personalized approach can reduce side effects and better control tumors. About 30 adults with stage III lung c…

This study looks at whether computer analysis of PET/CT scans can help doctors more accurately stage non-small cell lung cancer and predict genetic mutations. Researchers will use data from 500 patients to build and test machine learning models. The goal is to provide better, per…

This study tests whether a team of specialists (Molecular Tumor Board) can help choose better treatments for people with advanced lung cancer compared to usual care. About 659 participants with stage IIb-IV non-small cell lung cancer will be followed to see if the expert approach…

This study looks at how long Chinese patients with ALK-positive advanced lung cancer stay on brigatinib treatment in real-world settings. Researchers will also track cancer progression and response to the drug. About 154 participants are included, and the study simply observes th…

This study follows 160 lung cancer patients to see if their muscle mass, strength, and function are linked to how well they tolerate treatment and their overall survival. Researchers will also explore why some patients struggle to complete their therapy. The goal is to find ways …

This study tracks 1,000 people with advanced non-small cell lung cancer who are having surgery to remove lymph nodes. The goal is to see how often complications like nerve damage or bleeding happen and what factors make them more likely. By understanding these risks, doctors hope…

This study looks at patients with non-small-cell lung cancer that has spread only to the brain (fewer than 5 spots). Researchers will review different treatment strategies used at two hospitals to see which leads to longer survival without the disease getting worse. The goal is t…

This study tests a new technology that adjusts the radiation beam in real time to follow lung tumors as they move with breathing. About 20 adults with early-stage lung cancer or limited lung metastases will receive standard radiotherapy with this tracking system. The main goal is…

This study tests a new X-ray technique to track lung tumors during radiation without needing implanted markers. Five adults with early-stage lung cancer will be observed to see if the markerless method matches the standard marker-based tracking within 3 millimeters. If it works, …

This study is observing how well a combination of two immunotherapy drugs (nivolumab and ipilimumab) works for people with advanced non-small cell lung cancer in Italy. Researchers are collecting data from 404 patients to understand real-world outcomes, side effects, and treatmen…

This study looks at whether a computer model can analyze routine brain MRI scans to predict if a lung cancer that has spread to the brain has certain genetic changes (EGFR or ALK). The goal is to see if this noninvasive method can replace the need for a brain tumor biopsy to guid…

This study looks at how the immune system changes in 45 people with stage III non-small cell lung cancer who receive chemoradiation followed by the drug durvalumab. Researchers want to find immune markers that could predict how well the treatment works. The goal is to improve fut…

This study looks at the best way to collect tissue samples from lung cancer patients using a thin tube passed through the mouth (endobronchial ultrasound). It compares taking 2 versus 3 samples from each lymph node to see if fewer samples still provide enough material for genetic…

This study looks at a specific DNA repair issue called homologous recombination deficiency (HRD) in people with a type of lung cancer (EGFR-mutated NSCLC). Researchers want to know how common HRD is and whether it relates to how the cancer behaves. They will also test this in lab…

This study compares two ways of doing a lung biopsy (EBUS) for people with known or suspected non-small cell lung cancer. In one group, a cytotechnologist checks the tissue sample on-site during the procedure to give feedback. In the other group, no on-site check is done. The goa…

This study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…

This study looks at whether tiny particles called exosomes, found in blood and lung fluid, can predict how well treatment works in advanced lung cancer patients with fluid buildup around the lungs. Researchers will collect samples from 100 patients before and during standard ther…

This study observes how the drug osimertinib works in real-life settings for people with advanced lung cancer that has a specific genetic change (EGFR mutation). About 274 adults in France will be followed for up to 3 years to see how long they live, how their disease changes, an…

This study looks at whether food preferences can help predict undernutrition in people with stage IV non-small cell lung cancer who are starting their first treatment. About 190 participants will have their food cravings measured and receive personalized dietary advice if needed.…

This study looks at whether a special decision-making tool can help doctors and patients with advanced non-small cell lung cancer decide when to stop cancer treatments. The goal is to reduce the number of patients receiving chemotherapy or other treatments in their last days of l…

This study tests whether a remote monitoring system—including a smartphone app, a Fitbit, and a smart pill cap—can effectively track symptoms and side effects in 30 lung cancer patients taking oral targeted therapy. Participants will use the system for up to 24 weeks, and the goa…

This study is looking at 100 people with stage IIIA lung cancer who are getting treatment before surgery. Researchers want to see if a blood test that looks for tumor DNA (ctDNA) can predict how well patients do. If the tumor DNA disappears after treatment, it might mean a better…

This study aims to create a tool that can predict whether a cancer patient will benefit from their prescribed therapy. Researchers are analyzing blood samples from 10,000 people with advanced lung cancer or melanoma before and during treatment. The goal is to develop an algorithm…

This study tracks 300 patients with advanced non-small cell lung cancer whose tumors have low PD-L1 levels (below 1%). Researchers will look at side effects and healthcare use for different first-line treatments, including combinations of immunotherapy drugs like nivolumab and ip…

This study looks at whether bacteria in the gut and throat can predict how well stage III lung cancer patients respond to the immunotherapy drug durvalumab after chemoradiation. Researchers will collect stool, throat swabs, and breath samples from 126 participants to see if these…

This study looks at 80 lung cancer patients with complex conditions, like rare tumor types or previous radiation, to see how well radiotherapy works and what side effects occur. The goal is to gather information to help doctors make better treatment decisions for future patients.…

This study tracks 221 people with stage II or III lung cancer to see how chemoradiation therapy affects their heart health. Participants undergo heart scans, blood tests, and quality-of-life surveys before, during, and for at least two years after treatment. The goal is to better…

This study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. Th…

This observational study tracks over 5,000 people with non-small cell lung cancer to see how doctors use the VeriStrat blood test when deciding on treatment. Researchers want to learn if the test results change what therapy patients receive and whether new experimental tests can …

This study looks at how well immunotherapy works in people with advanced lung or head and neck cancers. Researchers will take blood samples before and after treatment to measure how the body clears the drug and how tumor cells in the blood change. The goal is to find markers that…